{"schema_version":"1.0","type":"article","title":"新藥能先在電腦裡試？「虛擬細胞」來了！","url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.md","lang":"zh-Hant","date":"2026-09-01","publish_at":"2026-09-01T07:00:00+08:00","updated_at":"2026-09-01","category":"商業分析系列","topic":"商業分析系列","tags":["AIDO Cell","GenBio AI","虛擬細胞","AI 製藥","單細胞","藥物發現","新方法學","X-Cell"],"summary":"GenBio AI 的 AIDO Cell 嘗試用共享狀態串起 DNA、RNA、蛋白質與細胞表型，並連續模擬基因、藥物與抗藥性擾動。公司基準顯示 31 項指標中有 24 項追平或超越專用模型，但目前只有 K-562、Hep-G2 兩種原型細胞，新預測仍待實體實驗、外部重現與盲測。","key_points":[],"facts":[],"sections":["01｜以前的模型會回答，虛擬細胞想學會「經歷」","02｜它現在到底做到了什麼？","03｜伊馬替尼案例，不是「神預測」","04｜為什麼藥廠仍會想要它？","05｜這不是一家公司獨跑的比賽","06｜FDA 的風向是利多，卻不是通行證","07｜台灣真正能切入的，不只是做一個中文版模型","08｜下一則新聞出現時，先看這四個驗證點","結語｜生物學開始可計算，但還沒有被算完","主要資料來源"],"references":[],"images":[{"alt":"圖 1｜細胞實驗不用做了？虛擬細胞來了！","url":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-01.png"},{"alt":"圖 2｜一顆會記得的數位細胞：共享狀態與連續擾動","url":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-02.png"},{"alt":"圖 3｜證據階梯：兩種原型細胞到獨立濕實驗，還差哪一步？","url":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-03.png"},{"alt":"圖 4｜商業閉環：資料、模型、實驗如何互相回饋","url":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-01）。新藥能先在電腦裡試？「虛擬細胞」來了！。https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}